Amneal revises OID on $250 million add-on term loan to 99.75

By Sara Rosenberg

New York, March 30 – Amneal Pharmaceuticals LLC modified the original issue discount on its $250 million add-on term loan to 99.75 from 99.509, according to a market source.

Pricing on the loan is Libor plus 350 basis points with a 1% Libor floor.

J.P. Morgan Securities LLC is the lead bank on the deal.

Proceeds will be used to fund a dividend and for general corporate purposes.

Amneal Pharmaceuticals is a Bridgewater, N.J.-based manufacturer of generic pharmaceuticals.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.